AGTR1 and focal segmental glomerulosclerosis: Treatment with selective endothelin A receptor blockers has been shown to provide a significant reduction in proteinuria, making it a useful tool in the treatment of FSGS, IgAN, and chronic kidney disease, mainly in combination with an AT1R antagonist (45–48).